Melanoma Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Cutaneous Melanoma, Ocular Melanoma, Mucosal Melanoma), By Therapy (Surgery, Immunotherapy, Targeted, Chemotherapy, Radiation), And By Geography - Forecasts From 2022 To 2027

  • Published : May 2022
  • Report Code : KSI061610401
  • Pages : 120

The melanoma treatment market is projected to witness a CAGR of 15.12% during the forecast period to reach a market size of US$9.608 billion by 2027, increasing from US$3.586 billion in 2020.


In recent years, there has been a rise in the number of new cases reported due to climatic changes. These changes are increasing the incidence of melanoma patients worldwide, raising the demand for proper methods of treatment. If detected and treated early, the disease is almost always curable. The rising per capita income, better health facilities, growing health awareness, the availability of health insurance services, and advancement in medical science and bio-medicines are additionally factoring in the expansion of the market.

Geographically, North America dominates the market share. The high prevalence of skin-related cancer in the United States is a major factor contributing to the market's growth. By type, cutaneous melanoma is widely spread globally and caused by too much exposure to ultraviolet rays from the sun and indoor tanning.  Based on therapy, targeted therapy is gaining the market share due to lesser side effects and high-efficiency rates.

Growth Factors

  • Growing regulatory approvals.

The high emphasis and consequently the elevated investment in the development of efficient treatment options are likely to have a positive impact on the growth of the market. Treatment recommendations depend on many factors, and the increasing number of regulatory approvals has made the highest impact on market growth. In 2021, Aldesleukin, Binimetinib, Braftovi (Encorafenib), Cobimetinib Fumarate, Cotellic (Cobimetinib Fumarate), Dabrafenib Mesylate, etc. were some of the approved drugs for the treatment by FDA. The emphasis of significant companies on introducing innovative treatment options and drugs will aid the market's growth in the coming years.

Impact of COVID-19 on the Melanoma Treatment Market

The pandemic has had a lagging effect on various diagnostic methods due to several restrictions and risk exposure of the comorbidity patients. A drastic reduction in skin biopsies was seen early in the COVID-19 pandemic, which disproportionately affected the elderly, females, and certain geographic regions. Efforts have been made by the government to contain the situation without further delay.

Competitive Insights

The market leaders for the melanoma treatment market are Merck & Co. Inc., Amgen Inc., Iovance Biotherapeutics, Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd., Novartis AG, Pfizer Inc., Sanofi, and AstraZeneca. 

  • In 2021, Oncosec Medical Inc. and Merck and Co. collaborated to study phase III metastatic melanoma.
  • In 2021, Amgen completed the acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share and is set to acquire Teneobio, a privately held, clinical-stage biotechnology company.
  • In 2020, Iovance Biotherapeutics, Inc sold $500 million of its common stock, subject to market and other conditions, in an underwritten public offering. In 2021, there has been certain turmoil, and the company is looking for buy-out options.
  • In 2019, Bristol-Myers Squibb Company and Celgene Corporation entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene for approximately $74 billion to create an innovative biopharma company.
  • In 2020, Novartis AG acquired The Medicines Company, and in 2018 GlaxoSmithKline plc reached an agreement with Novartis for the buyout of Novartis’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion. 
  • In 2020, FDA approved AstraZeneca and Merck & Co.'s drug selumetinib to treat neurofibromatosis type 1, or NF1, a rare and typically inherited disease that causes tumors to grow inside nerve sheaths. Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.

Melanoma Treatment Market Scope:

Report Metric Details
 Market size value in 2020  US$3.586 billion
 Market size value in 2027  US$9.608 billion
 Growth Rate  CAGR of 15.12% from 2020 to 2027
 Base year  2020
 Forecast period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments covered  Type, Therapy, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  Merck & Co. Inc., Amgen Inc., Iovance Biotherapeutics, Inc, Bristol-Myers Squibb, F.   Hoffmann-La Roche Ltd, Eisai Co., Ltd., Novartis AG, Pfizer Inc., Sanofi, AstraZeneca
 Customization scope  Free report customization with purchase


  • By Type
    • Cutaneous Melanoma
    • Ocular Melanoma
    • Mucosal Melanoma
  • By Therapy
    •  Surgery
    • Immunotherapy
    • Targeted Therapy
    • Chemotherapy
    • Radiation Therapy
  • By Geography
    • North America
      • USA
      • Canadá
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • Indonesia
      • Taiwan
      • Thailand
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the melanoma treatment market size by 2027?
A1. The melanoma treatment market is projected to reach a market size of US$9.608 billion by 2027.

Q2. What is the size of the global melanoma treatment market?
A2. Melanoma Treatment Market was valued at US$3.586 billion in 2020.

Q3. What are the growth prospects for the melanoma treatment market?
A3. The global melanoma treatment market is projected to witness a CAGR of 15.12% during the forecast period.

Q4. What factors are anticipated to drive the melanoma treatment market growth?
A4. The high emphasis and consequently the high investment in the development of efficient treatment options are likely to have a positive impact on the growth of the melanoma treatment market.

Q5. Which region holds the maximum market share of the melanoma treatment market?
A5. Geographically, North America holds the largest share of the melanoma treatment market owing to the high prevalence of skin-related cancer in the United States.

1.1. Market Definition
1.2. Market Segmentation

2.1. Research Data
2.2. Assumptions

3.1. Research Highlights

4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The Threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis

5.1. Cutaneous Melanoma
5.2. Ocular Melanoma
5.3. Mucosal Melanoma

6.1. Surgery
6.2. Immunotherapy
6.3. Targeted Therapy
6.4. Chemotherapy
6.5. Radiation Therapy

7.1. Introduction
7.2. North America
7.2.1. United States
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. Germany
7.4.2. France
7.4.3. United Kingdom 
7.4.4. Spain 
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. UAE
7.5.3. Israel
7.5.4. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. India
7.6.3. South Korea
7.6.4. Taiwan
7.6.5. Thailand
7.6.6. Indonesia 
7.6.7. Japan
7.6.8. Others

8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrative
8.3. Mergers, Acquisition, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix

9.1. Merck & Co. Inc.
9.2. Amgen Inc.
9.3. Iovance Biotherapeutics, Inc,
9.4. Bristol-Myers Squibb 
9.5. F. Hoffmann-La Roche Ltd
9.6. Eisai Co., Ltd.
9.7. Novartis AG
9.8. Pfizer Inc.
9.9. Sanofi
9.10. AstraZeneca

Merck & Co. Inc.

Amgen Inc.

Iovance Biotherapeutics, Inc,

Bristol-Myers Squibb 

F. Hoffmann-La Roche Ltd

Eisai Co., Ltd.

Novartis AG

Pfizer Inc.